Is Cencora (COR) A Bargain As Oncology Expansion And Q4 Estimates Come Into Focus?

Cencora (COR) just drew fresh attention after analysts outlined expectations for its upcoming quarter, highlighting projected earnings of $4.55 per share on US$88.16b in revenue, along with higher U.S. Healthcare Solutions operating income.

Cencora’s recent moves, including the planned American Oncology Network acquisition, have landed against a share price of US$330.84 and a 10.2% 1 month share price return. At the same time, the 1 year total shareholder return is slightly negative, while the 5 year total shareholder return above 170% signals that long term momentum has been strong even as near term sentiment has cooled.

Scan how Cencora compares with other potential breakouts by reviewing a hand picked set of 29 high quality undervalued stocks that pair strong fundamentals with compressed expectations.

Cencora looks like a heavyweight distributor with a long record of shareholder gains and a fresh oncology push, yet the recent run to around US$331 raises a simpler question: Are you paying up or still getting a deal?

Most Popular Narrative: 10% Undervalued

With Cencora last trading at $330.84 against a widely followed fair value estimate of about $369.31, the narrative frames the current price as leaving a cushion for investors who think its specialty focus and capital deployment plans will keep doing the heavy lifting.

The deepening focus on specialty pharmaceuticals through platforms such as OneOncology and Retina Consultants of America, which are currently performing ahead of initial expectations, positions Cencora to keep growing higher margin services that are likely to matter most for future operating income and earnings.

Active capital deployment that includes sizable share repurchases, such as the US$1.0b completed in fiscal Q3 2026 at an average price of US$268 per share alongside an additional US$2.0b authorization, can reduce the diluted share count over time and amplify the impact of operating income growth on per share earnings.

See why 28 investors see Cencora as 10% undervalued.

Result: Fair Value of $369.31 (UNDERVALUED)

Still, the Cencora story can be knocked off course if lower fee biosimilar and generic volumes weigh on margins, or if contract shifts repeat the Walgreens episode.

Find out about the key risks to this Cencora narrative.

Next Steps

With sentiment split between Cencora’s track record and the fresh oncology push, it helps to look past the headlines and weigh the trade off yourself. To see how the mix of concerns and bright spots stacks up in one view, start with the 4 key rewards and 2 important warning signs.

Looking for more Cencora sized investment ideas?

If Cencora has you thinking about portfolio upgrades, do not stop at a single ticker. Cast the net wider with a few focused stock lists.

• Target durable balance sheets by scanning companies in the list of solid balance sheet and fundamentals (25 results) that can better withstand shocks when conditions change.
• Hunt for quality at a discount with the 18 high quality undiscovered gems, where fundamentals do the talking before broad attention arrives.
• Prioritize sleep at night potential by reviewing the 30 resilient stocks with low risk scores that keep risk scores in check while still offering meaningful exposure.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com